This population of patients is at high risk of thrombosis at the time of surgery. The name of savino sciascia has been published incorrectly in the article, rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism 1, which appeared on p. In the rivaroxaban in antiphospholipid syndrome raps noninferiority trial, therefore, we aimed to confirm the usefulness of rivaroxaban in secondary prevention of venous thromboembolism in patients with antiphospholipid syndrome. Rivaroxaban a safe therapeutic option in patients with. Longterm anticoagulation with vitamin k antagonists vkas is the standard of care for preventing thrombosis in patients with antiphospholipid antibody syndrome aps, but vkas require frequent monitoring and are associated with food and drug interactions.
Thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus intervention. Use of direct oral anticoagulants in antiphospholipid syndrome. The use of direct oral anticoagulants in antiphospholipid. Listing a study does not mean it has been evaluated by the u. This randomised, controlled, openlabel, phase 23, noninferiority trial. Rivaroxaban, an orally active direct factor xa inhibitor, provides more consistent anticoagulation but its use in aps is controversial. Rivaroxaban use in patients with antiphospholipid syndrome a.
The use of rivaroxaban in patients with antiphospholipid syndrome. Treatment of the antiphospholipid syndrome with direct oral. Patients with thrombotic aps experience venous andor arterial thrombosis in association with persistent antiphospholipid antibodies. Hannah cohen about the results of the raps trial lancet haematol 2016.
We performed a multicenter feasibility study to examine our ability to identify and obtain consent from eligible aps patients and to obtain 95% adherence with daily rivaroxaban administration, in order to inform and power a larger study. Importantly, four out of a total of seven recurrent thrombotic events 571% in the rivaroxaban arm in pengo et al. Direct oral anticoagulants in antiphospholipid syndrome. Guidelines on the investigation and management of antiphospholipid syndrome. To determine whether rivaroxaban is noninferior to doseadjusted vitamin k antagonists vkas for thrombotic aps. Addendum to british society for haematology guidelines on. Rivaroxaban in antiphospholipid syndrome annals of internal. There is uncertainty regarding the safety and effectiveness of direct oral anticoagulant agents in patients with antiphospholipid syndrome aps. Rivaroxaban, a direct oral anticoagulant doac, is not noninferior to doseadjusted vitamin k antagonists in preventing thrombotic events in patients with antiphospholipid antibody syndrome aps, according to an industryfunded study in the annals of internal medicine. Diagnosis and management of the antiphospholipid syndrome. Microsoft powerpoint rivaroxaban vs warfarin in highrisk patients with antiphospholipid syndrome author. Thrombosis is one of the clinical hallmarks of antiphospholipid syndrome aps, but anticoagulant treatment with rivaroxaban xarelto, janssen pharmaceuticals may not be the optimal choice. Clinical outcomes of bleeding and thrombosis were also collected. Prevention of thrombosis in antiphospholipid syndrome.
Perioperative management of antiphospholipid antibody aplpositive patients is challenging because there are limited data on which to base recommendations. Rivaroxaban to treat thrombotic antiphospholipid syndrome thrombosis is one of the clinical hallmarks of antiphospholipid syndrome, a heterogeneous autoimmune disorder associated with the presence of antiphospholipid antibodies. Rivaroxaban in antiphospholipid syndrome annals of. Pdf thrombotic events in patients with antiphospholipid. With 54 patients in the rivaroxaban group and 56 patients in the warfarin group, the study by cohen and colleagues7 did not have su. Direct oral anticoagulants in antiphospholipid syndrome with. The traps rivaroxaban in thrombotic antiphospholipid syndrome. Rivaroxaban in antiphospholipid syndrome raps protocol. Catastrophic antiphospholipid antibody syndrome rarely, antiphospholipid antibody syndrome presents as acute multiorgan failure due to multiple vascular occlusions throughout the body the mortality rate of this severe complication is 50% d.
The objective was to develop evidencebased recommendations for the management of antiphospholipid syndrome aps in adults. Use of new oral anticoagulants in antiphospholipid syndrome. However, the use of warfarin is problematic, particularly in patients with antiphospholipid syndrome aps. Perioperative management of antiphospholipid antibody. Longterm anticoagulation with vitamin k antagonists vkas is the standard of care for preventing thrombosis in patients with antiphospholipid antibody syndrome aps, but vkas require frequent monitoring and. Doacs not recommended for people with antiphospholipid. The rivaroxaban in antiphospholipid syndrome raps study 1 suggests that. Aug 25, 2016 rivaroxaban is established for the treatment and secondary prevention of venous thromboembolism, but whether it is useful in patients with antiphospholipid syndrome is uncertain. In general, breastfeeding is considered acceptable when the rid is may 24, 2018 diagnosis and management of the antiphospholipid syndrome. We did the rivaroxaban in antiphospholipid syndrome. Failure of rivaroxaban to prevent thrombosis in four patients. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus raps. The traps rivaroxaban in thrombotic antiphospholipid syndrome study compared rivaroxaban 20 mg daily to warfarin target inr, 2. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome.
Jan, 2020 importantly, four out of a total of seven recurrent thrombotic events 571% in the rivaroxaban arm in pengo et al. Vitamin k antagonists for antiphospholipid antibody syndrome brady l. In the interim, rivaroxaban may be considered cautiously as an alternative anticoagulant in aps patients with poor anticoagulant control with vka. Dec 12, 2019 the traps rivaroxaban in thrombotic antiphospholipid syndrome study compared rivaroxaban 20 mg daily to warfarin target inr, 2. New oral anticoagulants in antiphospholipid syndrome treatment. Definition of the current role of doac s in the treatment of aps is based on limited. In thrombotic aps patients treated with rivaroxaban, the. Rivaroxaban for antiphospholipid antibody syndrome raps the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The use of direct oral anticoagulants in antiphospholipid syndrome. The rivaroxaban in antiphospholipid syndrome raps trial has closed to recruitment but final results have not yet been published. This question is currently being addressed in the rivaroxaban in antiphospholipid syndrome trial raps trial, a prospective randomized controlled trial of warfarin versus rivaroxaban in patients. Treatment effect was measured as the ratio of rivaroxaban to warfarin for thrombin.
These include the rivaroxaban versus warfarin to treat patients with antiphospholipid syndrome raps trial, the trial on rivaroxaban in antiphospholipid syndrome traps, rivaroxaban for antiphospholipid syndrome raps study clinicaltrial. Catastrophic antiphospholipid syndrome on switching from warfarin. The current mainstay of the treatment of thrombotic antiphospholipid syndrome aps is longterm anticoagulation with vitamin k antagonists vkas such as. The rivaroxaban in antiphospholipid syndrome raps randomized controlled trial rct, which had a laboratory surrogate primary outcome measure, suggests that rivaroxaban has the potential to be an effective and convenient alternative to warfarin in thrombotic aps patients with a single venous thromboembolism event requiring standard. Antiphospholipid syndrome aps is an acquired throm bophilia characterized by. Longterm anticoagulation with vitamin k antagonists vkas is the standard of care in thrombotic antiphospholipid syndrome aps but requires frequent monitoring and dose adjustment. Pdf rivaroxaban in antiphospholipid syndrome raps protocol. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban.
Rivaroxaban versus warfarin to treat patients with thrombotic. In the rivaroxaban in antiphospholipid syndrome raps noninferiority trial, therefore, we aimed to con. Rivaroxaban is an effective and safe alternative to warfarin in patients with atrial fibrillation and venous thromboembolism. Rivaroxaban for patients with antiphospholipid syndrome the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Apr 07, 2020 we read ordiros and colleagues study 1 comparing the efficacy and safety of rivaroxaban versus vitamin k antagonists vkas for secondary thromboprophylaxis in patients with antiphospholipid antibody syndrome aps with interest. The mechanism of action of these new anticoagulants involves the direct inhibition of either factor xa rivaroxaban, apixaban, edoxaban or. Patients on warfarin randomized to rivaroxaban started treatment when inr. After 3 years of followup, recurrent thrombosis occurred in 11 patients 11.
The current mainstay of the treatment of thrombotic antiphospholipid syndrome aps is longterm anticoagulation with. Aps can occur as a primary condition, or it can occur in the presence of systemic lupus erythematosus sle or another. Rivaroxaban to treat thrombotic antiphospholipid syndrome. Denasefficacy and safety of rivaroxaban vs warfarin in highrisk patients with antiphospholipid syndrome. Pdf use of direct oral anticoagulants in antiphospholipid syndrome. A larger trial raps rivaroxaban in antiphospholipid syndrome, irsctn 68222801 is ongoing and results will be available next year. Rivaroxaban versus warfarin to treat patients with. Recently, direct oral anticoagulants, including rivaroxaban have. Keeling d, mackie i, moore gw, greer ia, greaves m. Aps is a systemic autoimmune disease defined by thrombotic or obstetrical events that occur in.
Diagnosis and management of the antiphospholipid syndrome nejm. Rivaroxaban for antiphospholipid antibody syndrome full. Rivaroxaban in antiphospholipid syndrome raps is a phase iiiii prospective noninferiority rct in which eligible patients with aps, with or without sle, who are on warfarin, target international normalized ratio inr 2. Treatment of the antiphospholipid syndrome with direct. The standard treatment of vte historically consists of anticoagulation therapy with warfarin, a vitamin k antagonist. Nov 19, 2019 after 3 years of followup, recurrent thrombosis occurred in 11 patients 11. Oral anticoagulants in antiphospholipid syndrome 1037 46 merriman e, kaplan z, butler j, malan e, gan e, tran h. Eular recommendations for the management of antiphospholipid. Rivaroxaban and false positive lupus anticoagulant testing.
The current mainstay of treatment of thrombotic aps is longterm anticoagulation with oral vitamin k antagonists vka such as warfarin. This 3year randomized controlled trial compared the efficacy and safety of a newer oral anticoagulant versus doseadjusted vkas in patients with aps. The list of authors in the published html version should read. The medicines and healthcare products regulatory agency mhra has advised that directacting oral anticoagulants doacs should not be used in patients with antiphospholipid syndrome aps after a clinical trial found more thromboembolic events occurred with rivaroxaban compared with warfarin in patients with aps and a history of thrombosis. Directacting oral anticoagulants doacs, including xarelto, are not recommended for use in patients with a history of thrombosis who are diagnosed with antiphospholipid syndrome aps. Rivaroxaban versus vitamin k antagonist in antiphospholipid syndrome. We tested the efficacy and safety of rivaroxaban compared with warfarin in highrisk patients with thrombotic antiphospholipid syndrome.
The phase 23 risaps trial rivaroxaban for stroke patients with antiphospholipid syndrome aims to assess the efficacy of highintensity rivaroxaban at 15 mg twice daily vs that of highintensity warfarin, target inr 3. In the raps rivaroxaban in antiphospholipid syndrome trial, aps patients with at least one venous thromboembolism or. A low attenuated filling defect arrow in volving the pulmonary artery of the righ t lower lobe suggestive of a pulmonary embolism at the time of diagnosis. Methods study design traps is a prospective randomized phase 3 openlabel noninferiority study with blinded end point adjudication conducted in 14 centers in italy. Direct oral anticoagulants in antiphospholipid syndrome with venous. Anticoagulation in antiphospholipid antibody syndrome. Patients with antiphospholipid antibody syndrome aps that is triple positive for lupus anticoagulant, anticardiolipin, and anti. The new oral anticoagulants noac include dabigatran etexilate pradaxa, a direct thrombin inhibitor, and rivaroxaban xarelto, apixaban. Erratum the name of savino sciascia has been published incorrectly in the article, rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism 1, which appeared on p.
Stroke occurred more commonly in patients receiving rivaroxaban 9 events than in those receiving vkas 0 events corrected rr, 19. Rivaroxaban versus vitamin k antagonist in antiphospholipid. Rivaroxaban not noninferior to vkas for antiphospholipid. Antiphospholipid syndrome antiphospholipid antibodies can induce endothelialcell, complement, platelet, neutrophil, and monocyte activation, leading to thrombosis, renal failure, heart valve disea. Apr 16, 2014 rivaroxaban for antiphospholipid antibody syndrome raps the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. The potential role of new oral anticoagulants in antiphospholipid antibody syndrome aps remains uncertain.
Rivaroxaban, antiphospholipid syndrome introduction antiphospholipid syndrome aps is an autoimmune disease characterized by vascular thrombosis andor. Antiphospholipid syndrome aps is an autoimmune disease that is caused by antibodies against normal blood proteins that bind to cellmembrane phospholipids that can provoke thrombosis. Rivaroxaban use in patients with antiphospholipid syndrome. Rivaroxaban vs warfarin in highrisk patients with antiphospholipid syndrome. Antiphospholipid syndrome aps is a systemic autoimmune disease characterised by thromboembolic events including venous thromboembolism vte in association with the presence of antiphospholipid antibodies. Rivaroxaban in antiphospholipid syndrome raps isrctn. Rivaroxaban for patients with antiphospholipid syndrome. The traps trial trial on rivaroxaban in antiphospholipid syndrome, a randomized, open, multicenter noninferiority study with blinded end point adjudication compared the efficacy and safety of rivaroxaban, 20 mg once daily 15 mg once daily in impaired renal function with warfarin target inr 2. Doacs not recommended for people with antiphospholipid syndrome. Highrisk antiphospholipid antibody apl profile is associated with greater risk for thrombotic and obstetric aps.
Anticoagulant therapy is the mainstay of treatment for thrombotic aps. The standard treatment for secondary prevention of venous thromboembolism is vitamin k antagonists. In general, breastfeeding is considered acceptable when the rid is rivaroxaban. Oct 06, 2016 rivaroxaban for patients with antiphospholipid syndrome the safety and scientific validity of this study is the responsibility of the study sponsor and investigators. We read ordiros and colleagues study 1 comparing the efficacy and safety of rivaroxaban versus vitamin k antagonists vkas for secondary thromboprophylaxis in patients with antiphospholipid antibody syndrome aps with interest. Rivaroxaban is established for the treatment and secondary prevention of venous thromboembolism, but whether it is useful in patients with antiphospholipid syndrome is uncertain. Classification criteria of the antiphospholipid syndrome sapporo criteria1 clinical criteria. Rivaroxaban for thromboprophylaxis in patients with. Rivaroxaban vs warfarin in highrisk patients with antiphospholipid. Antiphospholipid syndrome aps is an acquired autoimmune. Direct oral anticoagulants in antiphospholipid syndrome scielo. Antiphospholipid syndrome aps is a systemic autoimmune disease characterized by venous or arterial thrombosis andor pregnancy loss in the presence of persistent expression over time of antiphospholipid antibodies apl. A singlearm feasibility cohort study of rivaroxaban in.
1479 1535 136 118 1033 145 21 1366 478 1320 986 1090 581 521 471 69 12 1479 1342 793 678 966 594 1217 1028 1266 1533 1152 828 1093 814 405 702 978 946 53 1108 1226 1349 308 1078 712 736 1070 525 840 213 1404